BTBP(SH:600161) Ge Long Hui·2025-09-30 08:57Core Viewpoint - Beijing Tiantan Biological Products Co., Ltd. has received approval from the National Medical Products Administration to conduct clinical trials for "human fibrinogen" [1] Company Summary - The product is classified as a therapeutic biological product with a specification of 0.5g (25ml) per bottle and is in injectable form [1] - The research and development investment for this product amounts to 5.9925 million yuan [1] - Indications for the product include congenital and acquired fibrinogen deficiency [1] Industry Summary - Several domestic companies produce similar products, while the international market includes competitors such as CSL Behring and Octapharma [1] - The product must complete multiple approval processes before it can be marketed, indicating uncertainty in drug development [1]